Thrombosis in vasculitis

Current Opinion in Rheumatology

Volumn 25, Issue 1, 2013, Pages 19-25

  Springer, Jason ^a   Villa Forte, Alexandra ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Deep venous thrombosis; pulmonary embolism; thrombosis; vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CD40 ANTIGEN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; FIBRONECTIN; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; RANTES; THROMBIN; THROMBOCYTE FACTOR 4; THROMBOPLASTIN; THROMBOSPONDIN; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VITRONECTIN; VON WILLEBRAND FACTOR;

ANCA ASSOCIATED VASCULITIS; ANTICOAGULATION; AORTA ARCH SYNDROME; ARTERY THROMBOSIS; BEHCET DISEASE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; GIANT CELL ARTERITIS; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFLAMMATION; ISCHEMIC HEART DISEASE; LOW DRUG DOSE; MORBIDITY; MORTALITY; POLYARTERITIS NODOSA; PRIORITY JOURNAL; REVIEW; SYSTEMIC VASCULITIS; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; VEIN THROMBOSIS;

BEHCET SYNDROME; HUMANS; INFLAMMATION; POLYARTERITIS NODOSA; THROMBOSIS; VASCULITIS; VENOUS THROMBOSIS;

EID: 84871194204     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835ad3ca     Document Type: Review

References (47)

1. Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet 2012; 379:244-249.
2. Zoller B, Li X, Sundquist J, Sundquist K. Risk of subsequent ischemic and hemorrhagic stroke in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. BMC Neurol 2012; 12:41.
3. Zoller B, Li X, Sundquist J, Sundquist K. Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PLo S One 2012; 7:e33442.
4. Ramagopalan SV, Wotton CJ, Handel AE, et al. Risk of venous thromboem-bolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med 2011;9:1.
5. von Scheven E, Lu TT, Emery HM, et al. Thrombosis and pediatric Wegener's granulomatosis: acquired and genetic risk factors for hypercoagulability. Arthritis Rheum 2003; 49:862-865.
6. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Eta-nercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361.
7. Leung L, Morser J. Inflammatory Diseases of Blood Vessels. 2nd ed. In: Hoffman G, Weyand C, Langford C, Goronzy J, editors. Hemostasis and vascular inflammation. New Delhi, India: Blackwell Publishing Ltd; 2012. p. 105.
8. Margetic S. Inflammation and haemostasis. Biochem Med (Zagreb) 2012; 22:49-62.
9. Wojcik BM, Wrobleski SK, Hawley AE, et al. Interleukin-6: a potential target for postthrombotic syndrome. Ann Vasc Surg 2011; 25:229-239.
10. Ramacciotti E, Blackburn S, Hawley AE, et al. Evaluation ofsoluble P-selectin as a marker for the diagnosis of deep venous thrombosis. Clin Appl Thromb Hemost 2011; 17:425-431.
11. Gremmel T, Ay C, Seidinger D, et al. Soluble p-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb. J Vasc Surg 2011;54(6 Suppl):48S-55S.
12. Meier TR, Myers DD Jr, Wrobleski SK, et al. Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagula-tion. Thromb Haemost 2008; 99:343-351.
13. Duzgun N, Ates A, Aydintug OT, et al. Characteristicsofvascular involvement in Behcet's disease. Scand J Rheumatol 2006; 35:65-68.
14. Kisacik B, Oren C, Kasifoglu T, et al. Investigation of the veins in patientswith Behcet's disease with no known vascular event by Doppler ultrasonography. Rheumatol Int 2012; 32:303-306.
15. Desbois A, Wechsler B, Resche Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Behcet's disease. Arthritis Rheum 2012; 64:2753-2760.
16. Ahn JK, Lee YS, Jeon CH, et al. Treatmentofvenousthrombosisassociatedwith Behcet's disease: immunosuppressive therapy alone versus immunosuppres-sive therapy plus anticoagulation. Clin Rheumatol 2008; 27:201-205.
17. Aguiar de Sousa D, Mestre T, Ferro JM. Cerebral venous thrombosis in Behcet's disease: a systematic review. J Neurol 2011; 258:719-727.
18. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari syndrome: a common complication of Behcet's disease. Am J Gastroenterol 1997; 92:858-862.
19. Ben Ghorbel I, Ennaifer R, Lamloum M, et al. Budd-Chiari syndrome asso-ciated with Behcet's disease. Gastroenterol Clin Biol 2008; 32:316-320.
20. Saadoun D, Wechsler B, Resche-Rigon M, et al. Cerebral venous thrombosis in Behcet's disease. Arthritis Rheum 2009; 61:518-526.
21. Yesilot N, Bahar S, Yilmazer S, et al. Cerebral venous thrombosis in Behcet's disease compared to those associated with other etiologies. J Neurol 2009; 256:1134-1142.
22. Onur E, Kabaroglu C, Inanir I, et al. Oxidative stress impairs endothelial nitric oxide levels in Behcets' disease. Cutan Ocul Toxicol 2011; 30:217-220.
23. Lee YH, Song GG. Associations between e NOS polymorphisms and sus-ceptibility to Behcet'sdisease: ameta-analysis. J Eur Acad Dermatol Venereol 2011; 26:1266-1271.
24. Kavala M, Namdar ND, Kocaturk E, et al. Activated protein Cresistanceand its correlation with thrombophlebitis in Behcet's disease. Acta Dermatovenerol Croat 2011; 19:87-90.
25. Navarro S, Bonet E, Medina P, et al. Haplotypes of the endothelial protein C receptor gene and Behcet's disease. Thromb Res 2012; 129:459-464.
26. Owens AP 3rd, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108:1284-1297.
27. Macey M, Hagi-Pavli E, Stewart J, et al. Age, gender and disease-related platelet and neutrophil activation ex vivo in whole blood samples from patients with Behcet's disease. Rheumatology (Oxford) 2011; 50:1849-1859.
28. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990; 322:281-285.
29. Merkel PA, Lo GH, Holbrook JT, et al. Briefcommunication: high incidence of venousthrombotic eventsamong patientswith Wegenergranulomatosis: the Wegener's Clinical Occurrence of Thrombosis (We CLOT) Study. Ann Intern Med 2005; 142:620-626.
30. Allenbach Y, Seror R, Pagnoux C, et al. High frequency of venous throm-boembolic events in Churg-Strauss syndrome, Wegener's granulomatosis and microscopic polyangiitis but not polyarteritis nodosa: a systematic retro-spective study on 1130 patients. Ann Rheum Dis 2009; 68:564-567.
31. Glynn RJ, Danielson E, Fonseca FA, et al. A randomized trial of rosuvastatin in the prevention ofvenousthromboembolism. N Engl J Med 2009; 360:1851-1861.
32. Rodriguez AL, Wojcik BM, Wrobleski SK, et al. Statins, inflammation and deep vein thrombosis: a systematic review. J Thromb Thrombolysis 2012; 33:371-382.
33. Morgan MD, Turnbull J, Selamet U, et al. Increased incidence of cardiovas-cular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 2009; 60:3493-3500.
34. Faurschou M, Mellemkjaer L, Sorensen IJ, et al. Increased morbidity from ischemic heart disease in patients with Wegener's granulomatosis. Arthritis Rheum 2009; 60:1187-1192.
35. Suppiah R, Judge A, Batra R, et al. A modeltopredictcardiovascularevents in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. Arthritis Care Res (Hoboken) 2011; 63:588-596.
36. Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Venous thromboem-bolism in ANCA-associated vasculitis: incidence and riskfactors. Rheuma-tology (Oxford) 2008; 47:530-534.
37. Bautz DJ, Preston GA, Lionaki S, et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol 2008; 19:2421-2429.
38. Pendergraft WFrd, Preston GA, Shah RR, et al. Autoimmunityistriggered by c PR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10:72-79.
39. Sebastian JK, Voetsch B, Stone JH, et al. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a throm-botic event. J Rheumatol 2007; 34:2446-2450.
40. Moosbauer C, Morgenstern E, Cuvelier SL, et al. Eosinophils are a major intravascular location for tissue factor storage and exposure. Blood 2007; 109:995-1002.
41. Maino A, Rossio R, Cugno M, et al. Hypereosinophilic Syndrome, Churg-Strauss Syndrome and parasitic diseases: possible Links between Eosino-philia and Thrombosis. Curr Vasc Pharmacol 2012; 10:670-675.
42. Ames PR, Margaglione M, Mackie S, Alves JD. Eosinophiliaand thrombophilia in churg strauss syndrome: a clinical and pathogenetic overview. Clin Appl Thromb Hemost 2010; 16:628-636.
43. Maksimowicz-Mc Kinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease? Medicine (Baltimore) 2009; 88:221-226.
44. Hwang J, Kim SJ, Bang OY, et al. Ischemic stroke in Takayasu's Arteritis: lesion patterns and possible mechanisms. J Clin Neurol 2012; 8:109-115.
45. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50:1332-1337.
46. De Souza AW, Machado NP, Pereira VM, et al. Antiplatelet therapy for the prevention of arterial ischemic events in takayasu arteritis. Circ J 2010; 74:1236-1241.
47. Narvaez J, Bernad B, Nolla JM, Valverde J. Statin therapy does not seem to benefit giant cell arteritis. Semin Arthritis Rheum 2007; 36:322-327.